RNA Analytical/Quality Videos

  1. The "Golden Idea Of The Platform" & Its Role In mRNA PD 8/22/2024

    Explore how early-stage companies can implement design space and analytical principles that will help us determine the biggest differences between constructs and how close we may be to a true “platform process.”

  2. The 20-Method Hurdle: Confronting the Operational Burden of mRNA Release 6/9/2026

    Though this Advancing RNA Live panel believes we’re still at too early a stage to begin reducing the number of methods we need for release, Sanofi’s Philippe Talaga, AbbVie’s Elaine Peters, and Tessera’s Ilya Shestopalov had a few ideas on what we can/should be doing today to set us up for more streamlined release panels in the future.  

  3. How Analytical Development Is Informing mRNA Process Development Today 8/22/2024

    In this clip, Advancing RNA LIVE, panelists, share their perspectives on how advancements in RNA analytical development are complementing and informing process development efforts for linear mRNA.

  4. Next-Gen Analytical Methods to Watch in mRNA-LNP Development 6/9/2026

    In the opening clip from this Advancing RNA Live event, AbbVie’s Elaine Peters, Sanofi’s Philippe Talaga, and Tessera’s Ilya Shestopalov share the novel methods they’ve been watching the most closely in the mRNA-LNP development space, as well as the role these methods will play in elucidating more about our drug products’ quality attributes. 

  5. mRNA/saRNA Manufacturing: Accelerate The Path To Clinic 3/22/2021

    Discover key upstream and downstream considerations for process development for RNA drug substance manufacturing and the parameters that need construct-specific optimization to increase yield and reduce impurities.

  6. What The EMA Guidance Means For mRNA: Progress, Limitations, And Future Directions 6/24/2025

    Advancing RNA panelists Tiffany Lucas and Ulrike Jägle home in on the EMA’s guidance for mRNA vaccine quality, sharing their initial thoughts on the guidance’s strengths, while also addressing its limitations for those of us who may be working with mRNA in a therapeutic context.

  7. Beyond Solid Phase: Weighing Supply Chain Readiness For Liquid Phase & Hybrid Oligo Synthesis 12/3/2025

    The oligo manufacturing paradigm is facing several different evolutions whether it be the transition to liquid-phase or hybrid synthesis. In this Advancing RNA Live clip, Camp4’s Satya Kuchimanchi explores how these manufacturing advancements are impacting our supply chain needs.

  8. How A Sponsored CMC Platform Accelerates mRNA Projects Into The Clinic 1/31/2023

    Developing a client-sponsored Target Product Profile (TPP) and Analytical Target Profile (ATP) is critical to move your drug product to clinic efficiently and meet acceptance criteria.

  9. Navigating the Continuum of LNP Analytical Knowledge 6/9/2026

    In this clip, Advancing RNA Live speakers Elaine Peters, Philippe Talaga, and Ilya Shestopalov advocate for an orthogonal approach as we strive to better understand our LNP QAs — with particular attention paid to particle size.   

  10. Crafting A "Durable" Partnership: A Two-Pronged Approach

    Featured speakers for the "Got Raw Materials? The State Of The mRNA Supply Chain" event share how they are working to deepen their partnerships today.